Literature DB >> 34519330

Cortical Serotonergic and Catecholaminergic Denervation in MPTP-Treated Parkinsonian Monkeys.

Gunasingh Jeyaraj Masilamoni1,2, Allison Weinkle1, Stella M Papa1,3, Yoland Smith1,2,3.   

Abstract

Decreased cortical serotonergic and catecholaminergic innervation of the frontal cortex has been reported at early stages of Parkinson's disease (PD). However, the limited availability of animal models that exhibit these pathological features has hampered our understanding of the functional significance of these changes during the course of the disease. In the present study, we assessed longitudinal changes in cortical serotonin and catecholamine innervation in motor-symptomatic and asymptomatic monkeys chronically treated with low doses of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP). Densitometry and unbiased stereological techniques were used to quantify changes in serotonin and tyrosine hydroxylase (TH) immunoreactivity in frontal cortices of 3 control monkeys and 3 groups of MPTP-treated monkeys (motor-asymptomatic [N = 2], mild parkinsonian [N = 3], and moderate parkinsonian [N = 3]). Our findings revealed a significant decrease (P < 0.001) in serotonin innervation of motor (Areas 4 and 6), dorsolateral prefrontal (Areas 9 and 46), and limbic (Areas 24 and 25) cortical areas in motor-asymptomatic MPTP-treated monkeys. Both groups of symptomatic MPTP-treated animals displayed further serotonin denervation in these cortical regions (P < 0.0001). A significant loss of serotonin-positive dorsal raphe neurons was found in the moderate parkinsonian group. On the other hand, the intensity of cortical TH immunostaining was not significantly affected in motor asymptomatic MPTP-treated monkeys, but underwent a significant reduction in the moderate symptomatic group (P < 0.05). Our results indicate that chronic intoxication with MPTP induces early pathology in the corticopetal serotonergic system, which may contribute to early non-motor symptoms in PD. Published by Oxford University Press 2021.

Entities:  

Keywords:  dopamine; noradrenaline; prefrontal cortex; primary motor cortex; serotonin

Mesh:

Substances:

Year:  2022        PMID: 34519330      PMCID: PMC9070356          DOI: 10.1093/cercor/bhab313

Source DB:  PubMed          Journal:  Cereb Cortex        ISSN: 1047-3211            Impact factor:   4.861


  142 in total

1.  [¹⁸F]FDOPA uptake in the raphe nuclei complex reflects serotonin transporter availability. A combined [¹⁸F]FDOPA and [¹¹C]DASB PET study in Parkinson's disease.

Authors:  N Pavese; B S Simpson; V Metta; A Ramlackhansingh; K Ray Chaudhuri; D J Brooks
Journal:  Neuroimage       Date:  2011-09-22       Impact factor: 6.556

2.  Spatial and non-spatial working memory at different stages of Parkinson's disease.

Authors:  A M Owen; J L Iddon; J R Hodges; B A Summers; T W Robbins
Journal:  Neuropsychologia       Date:  1997-04       Impact factor: 3.139

3.  Interaction between cognitive and motor cortico-basal ganglia loops during decision making: a computational study.

Authors:  M Guthrie; A Leblois; A Garenne; T Boraud
Journal:  J Neurophysiol       Date:  2013-03-27       Impact factor: 2.714

4.  Metabotropic glutamate receptor 5 antagonist protects dopaminergic and noradrenergic neurons from degeneration in MPTP-treated monkeys.

Authors:  Gunasingh J Masilamoni; James W Bogenpohl; David Alagille; Kristen Delevich; Gilles Tamagnan; John R Votaw; Thomas Wichmann; Yoland Smith
Journal:  Brain       Date:  2011-07       Impact factor: 13.501

Review 5.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

6.  Evaluation of the noradrenergic system in Parkinson's disease: an 11C-MeNER PET and neuromelanin MRI study.

Authors:  Michael Sommerauer; Tatyana D Fedorova; Allan K Hansen; Karoline Knudsen; Marit Otto; Jesper Jeppesen; Yoon Frederiksen; Jakob U Blicher; Jacob Geday; Adjmal Nahimi; Malene F Damholdt; David J Brooks; Per Borghammer
Journal:  Brain       Date:  2018-02-01       Impact factor: 13.501

7.  Extrastriatal D2-like receptors modulate basal ganglia pathways in normal and Parkinsonian monkeys.

Authors:  Arash Hadipour-Niktarash; Karen S Rommelfanger; Gunasingh J Masilamoni; Yoland Smith; Thomas Wichmann
Journal:  J Neurophysiol       Date:  2011-11-30       Impact factor: 2.714

8.  Loss of brainstem serotonin- and substance P-containing neurons in Parkinson's disease.

Authors:  G M Halliday; P C Blumbergs; R G Cotton; W W Blessing; L B Geffen
Journal:  Brain Res       Date:  1990-02-26       Impact factor: 3.252

9.  Metabotropic glutamate receptor 4 in the basal ganglia of parkinsonian monkeys: ultrastructural localization and electrophysiological effects of activation in the striatopallidal complex.

Authors:  James Bogenpohl; Adriana Galvan; Xing Hu; Thomas Wichmann; Yoland Smith
Journal:  Neuropharmacology       Date:  2012-05-23       Impact factor: 5.250

10.  Dissociable effects of dopaminergic therapy on spatial versus non-spatial working memory in Parkinson's disease.

Authors:  H Mollion; J Ventre-Dominey; P F Dominey; E Broussolle
Journal:  Neuropsychologia       Date:  2003       Impact factor: 3.139

View more
  1 in total

1.  Induced Cognitive Impairments Reversed by Grafts of Neural Precursors: A Longitudinal Study in a Macaque Model of Parkinson's Disease.

Authors:  Florence Wianny; Kwamivi Dzahini; Karim Fifel; Charles Robert Eden Wilson; Agnieszka Bernat; Virginie Dolmazon; Pierre Misery; Camille Lamy; Pascale Giroud; Howard Michael Cooper; Kenneth Knoblauch; Emmanuel Procyk; Henry Kennedy; Pierre Savatier; Colette Dehay; Julien Vezoli
Journal:  Adv Sci (Weinh)       Date:  2022-02-09       Impact factor: 16.806

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.